NCT01652898View on ClinicalTrials.gov

A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

August 31, 2012

Conditions
Healthy
Interventions
DRUG

LDLA202

Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points

DRUG

ONO LDL50

Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points

DRUG

Esmolol hydrochloride

Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points

Trial Locations (1)

323 00

Cepha s.r.o, Pilsen

Sponsors
All Listed Sponsors
lead

AOP Orphan Pharmaceuticals AG

INDUSTRY

NCT01652898 - A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers | Biotech Hunter | Biotech Hunter